Q&A: What’s Next for PLOS

A conversation with outgoing Chief Executive Officer Elizabeth Marincola

Written byTracy Vence
| 3 min read

Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share

Elizabeth Marincola at Wikimania 2014WIKIMEDIA, MIKE PEELIn October, PLOS announced that Chief Executive Officer Elizabeth Marincola will be leaving the nonprofit at the end of this year. The Scientist recently spoke with Marincola about the future of open-access publishing and what we can expect from PLOS following her departure.

The Scientist: You’ve led PLOS for more than three years now. What are some of the highlights of your time with the organization?

Elizabeth Marincola: We have continued to serve our mission, probably most notably in launching a publishing platform we designed and built from the ground up, called Aperta. And it’s meant to be able to substitute for the commercial platforms available that are generally found to be quite unsatisfying, un-user-friendly. So we are very proud of that, and we already have many publishers who are eager to get their hands on it.

In addition, we have rolled out an open-data policy that we feel really has led the way in terms of demanding that all relevant published research be made available. And we ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies